D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Clinical trial NCT04206072 · COMPLETED

Trial details

NCT number: NCT04206072
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer EGFR Gene Mutation

Start date: 2019-12-24
Primary completion: 2022-07-30
Enrollment: 362

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.